Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, 79430, USA.
Am J Med Sci. 2011 Dec;342(6):507-12. doi: 10.1097/MAJ.0b013e31821790f4.
Pulmonary hypertension is a complex disorder with multiple etiologies. The World Health Organization Group 5 (unclear multifactorial mechanisms) includes patients with thyroid disorders. The authors reviewed the literature on the association between hyperthyroidism and pulmonary hypertension and identified 20 publications reporting 164 patients with treatment outcomes. The systolic pulmonary artery (PA) pressures in these patients ranged from 28 to 78 mm Hg. They were treated with antithyroid medications, radioactive iodine and surgery. The mean pretherapy PA systolic pressure was 39 mm Hg; the mean posttreatment pressure was 30 mm Hg. Pulmonary hypertension should be considered in hyperthyroid patients with dyspnea. All patients with pulmonary hypertension should be screened for hyperthyroidism, because the treatment of hyperthyroidism can reduce PA pressures, potentially avoid the side-effects and costs with current therapies for pulmonary hypertension and limit the consequences of untreated hyperthyroidism. However, the long-term outcome in these patients is uncertain, and this issue needs more study. Changes in the pulmonary circulation and molecular regulators of vascular remodeling likely explain this association.
肺动脉高压是一种病因复杂的疾病。世界卫生组织第 5 组(原因不明的多因素机制)包括甲状腺疾病患者。作者查阅了关于甲状腺功能亢进症与肺动脉高压之间关系的文献,共找到 20 篇报道 164 例患者的治疗结果的文献。这些患者的收缩期肺动脉(PA)压力范围为 28 至 78mmHg。他们接受了抗甲状腺药物、放射性碘和手术治疗。治疗前 PA 收缩压的平均为 39mmHg;治疗后平均压力为 30mmHg。对于有呼吸困难的甲状腺功能亢进症患者,应考虑肺动脉高压。所有肺动脉高压患者都应筛查甲状腺功能亢进症,因为治疗甲状腺功能亢进症可以降低 PA 压力,可能避免目前肺动脉高压治疗的副作用和费用,并限制未经治疗的甲状腺功能亢进症的后果。然而,这些患者的长期结果尚不确定,这个问题需要更多的研究。肺循环和血管重塑的分子调节剂的变化可能解释了这种关联。